ClinConnect ClinConnect Logo
Search / Trial NCT03930953

A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL)

Launched by CELGENE · Apr 25, 2019

Trial Information

Current as of July 24, 2025

Recruiting

Keywords

Non Hodgkin Lymphomas (Nhl) Safety Efficacy Cc 99282 Rituximab Relapsed Refractory Pharmacokinetics Obinutuzumab Tafasitamab Valemetostat Anti Lymphoma Agents

ClinConnect Summary

This clinical trial is studying a new treatment called CC-99282, both on its own and combined with other medications, for people with relapsed or refractory non-Hodgkin lymphoma (NHL). This means it is looking at how safe the treatment is and if it can help patients whose lymphoma has not responded to previous therapies. The trial is currently recruiting participants who are between the ages of 65 and 74 and are in fairly good health, as indicated by their performance status.

To be eligible for the trial, participants must have a history of non-Hodgkin lymphoma that has come back after treatment or has not responded to treatment. They should not have any serious heart issues or conditions that would significantly shorten their life expectancy. Participants can expect regular check-ups and monitoring during the trial to ensure their safety and to see how well the treatment works. It’s a chance to access a new therapy that might provide benefits for their condition.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • History of Non-Hodgkin's Lymphoma (NHL) with relapsed or refractory disease
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
  • Exclusion Criteria:
  • Life expectancy ≤ 2 months
  • Received prior systemic anti-cancer treatment (approved or investigational) ≤ 5 half-lives or 4 weeks prior to starting CC-99282, whichever is shorter
  • Is on chronic systemic immunosuppressive therapy or corticosteroids or has clinically significant graft-versus-host disease (GVHD)
  • Impaired cardiac function or clinically significant cardiac disease
  • Other protocol-defined inclusion/exclusion criteria apply

About Celgene

Celgene, now a part of Bristol Myers Squibb, is a global biopharmaceutical company dedicated to advancing innovative therapies for patients with cancer and other serious diseases. With a strong emphasis on research and development, Celgene focuses on discovering and delivering transformative medicines that address unmet medical needs. The company is committed to enhancing patient outcomes through rigorous clinical trials, cutting-edge science, and collaboration with healthcare professionals, ultimately striving to improve the quality of life for patients worldwide.

Locations

Rouen, , France

Jacksonville, Florida, United States

Hackensack, New Jersey, United States

Malaga, , Spain

Saint Louis, Missouri, United States

Houston, Texas, United States

Paris, , France

Madrid, , Spain

Sao Paulo, Sp, Brazil

Salamanca, , Spain

Copenhagen, , Denmark

Buenos Aires, , Argentina

Jerusalem, , Israel

Leuven, , Belgium

Vienna, , Austria

Bologna, , Italy

Edegem, , Belgium

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

La Jolla, California, United States

Creteil, , France

Vejle, , Denmark

Guangzhou, Guangdong, China

Guangzhou, Guangdong, China

Jerusalem, , Israel

Guangzhou, , China

Aarhus, , Denmark

Bordeaux, , France

Porto Alegre, Rio Grande Do Sul, Brazil

Toronto, Ontario, Canada

Bergamo, , Italy

Shenyang, Liaoning, China

Paris, , France

Napoli, , Italy

Montpellier Cedex 5, , France

Beijing, Beijing, China

Zhengzhou, Henan, China

Busan, , Korea, Republic Of

Tianjin, Tianjin, China

Villejuif Cedex, , France

Barcelona, , Spain

Napoli, , Italy

Shanghai, Shanghai, China

Milano, , Italy

Badalona (Barcelona), , Spain

Edinburgh Scotland, , United Kingdom

Salzburg, , Austria

Scottsdale, Arizona, United States

Tampa, Florida, United States

Whittier, California, United States

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Seoul, , Korea, Republic Of

Madrid, , Spain

Pierre Benite Cedex, , France

Southhampton, , United Kingdom

Toulouse, , France

Shenyang, Liaoning, China

Rochester, Minnesota, United States

London, , United Kingdom

Shenyang, Liaoning, China

Leuven, , Belgium

Lillie Cedex, , France

Seoul, Seoul, Korea, Korea, Republic Of

Villejuif Cedex, , France

Overland Park, Kansas, United States

Tianjin, Tianjin, China

Guangzhou, Guangdong, China

Orange, California, United States

Mineola, New York, United States

Sankt Pölten, , Austria

Edmonton, Alberta, Canada

Montreal, , Canada

Aarhus C, , Denmark

Creteil, , France

Lillie Cedex, , France

Montpellier Cedex 5, , France

Bologna, , Italy

Barcelona, , Spain

Madrid, , Spain

Malaga, , Spain

Belfast Northern Ireland, , United Kingdom

Madrid, , Spain

Baltimore, Maryland, United States

Montpellier Cedex 5, , France

Santiago, , Chile

Paris, , France

Toulouse, , France

Jerusalem, , Israel

Petah Tikva, , Israel

Edinburgh Scotland, , United Kingdom

Los Angeles, California, United States

Ciudad Autónoma De Buenos Aires, Buenos Aires, Argentina

Buenos Aires, , Argentina

Cordoba, , Argentina

Santiago, Metropolitana, Chile

Santiago, Metropolitana, Chile

Las Condes, Santiago De Chile, Chile

Santiago, , Chile

Vejle, , Denmark

Bordeaux, , France

Sankt Pölten, , Austria

Vienna, , Austria

Bergamo, , Italy

Badalona (Barcelona), , Spain

Aarhus, , Denmark

Ramat Gan, , Israel

Milano, , Italy

Rozzano, , Italy

Leuven, , Belgium

Porto Alegre, Rio Grande Do Sul, Brazil

Sao Paulo, Sp, Brazil

Sao Paulo, , Brazil

São Paulo, , Brazil

Toronto, Ontario, Canada

Las Condes, Arica Y Parinacota, Chile

Copenhagen, , Denmark

Pierre Benite Cedex, , France

Santiago De Chile, Metropolitana, Chile

Salzburg, , Austria

Edegem, , Belgium

Edmonton, Alberta, Canada

Rouen, , France

Napoli, , Italy

Salamanca, , Spain

Belfast Northern Ireland, , United Kingdom

Southhampton, , United Kingdom

Busan, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Pilar, Buenos Aires, Argentina

Buenos Aires, , Argentina

Pavia, , Italy

Recoleta, Metropolitana, Chile

Overland Park, Kansas, United States

Ciudad Autonoma De Buenos Aires, Buenos Aires, Argentina

Verona, , Italy

Haerbin, Heilongjiang, China

Hangzhou, Zhejiang, China

Xiamen, Fujian, China

Guangzhou, , China

Santiago, Rm, Chile

Beijing, Beijing, China

Guangzhou, Guangdong, China

Zhengzhou, Henan, China

Wuhan Shi, Hubei, China

Shenyang, Liaoning, China

Shenyang, Liaoning, China

Shanghai, Shanghai, China

Tianjin, Tianjin, China

Guangzhou, , China

São Paulo, , Brazil

Santiago, Metropolitana De Santiago, Chile

Montpellier, , France

Toulouse, , France

St. Polten, , Austria

São Paulo, , Brazil

Santiago, Metropolitana De Santiago, Chile

Santiago, Metropolitana, Chile

Santiago, Rm, Chile

Beijing, Beijing, China

Hackensack, New Jersey, United States

Recoleta, Metropolitana, Chile

Wuhan Shi, Hubei, China

Barcelona, , Spain

São Paulo, , Brazil

Ramat Gan, , Israel

Madrid, , Spain

Mineola, New York, United States

Saint Louis, Missouri, United States

Santiago, Metropolitana, Chile

Buenos Aires, , Argentina

Patients applied

0 patients applied

Trial Officials

Bristol-Myers Squibb

Study Director

Bristol-Myers Squibb

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials